Emma Dean

5.5k total citations · 1 hit paper
132 papers, 2.7k citations indexed

About

Emma Dean is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Emma Dean has authored 132 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 75 papers in Molecular Biology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Emma Dean's work include PARP inhibition in cancer therapy (40 papers), DNA Repair Mechanisms (33 papers) and Lung Cancer Treatments and Mutations (19 papers). Emma Dean is often cited by papers focused on PARP inhibition in cancer therapy (40 papers), DNA Repair Mechanisms (33 papers) and Lung Cancer Treatments and Mutations (19 papers). Emma Dean collaborates with scholars based in United Kingdom, United States and France. Emma Dean's co-authors include Malcolm Ranson, Caroline Dive, Alastair Greystoke, Mark R. Middleton, Fiona Blackhall, Simon A. Smith, Helen Swaisland, Ruth Plummer, Peter G. Mortimer and Timothy H. Ward and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Emma Dean

127 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

2021 192 citations Hendrik‐Tobias Arkenau, Emma Dean et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emma Dean United Kingdom	29	1.8k	1.4k	436	390	256	132	2.7k
Antonella Papa United States	18	2.4k 1.3×	855 0.6×	560 1.3×	390 1.0×	247 1.0×	29	3.1k
T. Khanh United States	26	1.6k 0.9×	991 0.7×	473 1.1×	462 1.2×	238 0.9×	57	2.5k
Patrick G. Pilié United States	13	1.1k 0.6×	1.1k 0.7×	342 0.8×	407 1.0×	227 0.9×	43	1.8k
Giulio Francia United States	31	1.5k 0.9×	1.5k 1.0×	849 1.9×	540 1.4×	346 1.4×	69	3.2k
Thomas Bogenrieder Germany	25	1.2k 0.7×	1.2k 0.8×	536 1.2×	342 0.9×	371 1.4×	63	2.6k
Giorgio Valabrega Italy	28	946 0.5×	1.8k 1.3×	497 1.1×	490 1.3×	477 1.9×	115	2.8k
Ben Markman Australia	24	1.3k 0.8×	1.2k 0.8×	329 0.8×	489 1.3×	219 0.9×	75	2.5k
Shaozhen Xie United States	21	1.5k 0.8×	1.5k 1.0×	392 0.9×	930 2.4×	743 2.9×	30	3.0k
Sohye Kang United States	16	1.9k 1.1×	695 0.5×	353 0.8×	379 1.0×	175 0.7×	18	2.4k
Daniele Fanale Italy	29	1.2k 0.7×	979 0.7×	922 2.1×	437 1.1×	274 1.1×	84	2.5k

Countries citing papers authored by Emma Dean

Since Specialization

Citations

This map shows the geographic impact of Emma Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Dean more than expected).

Fields of papers citing papers by Emma Dean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Dean. The network helps show where Emma Dean may publish in the future.

Co-authorship network of co-authors of Emma Dean

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Dean. A scholar is included among the top collaborators of Emma Dean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Dean. Emma Dean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, David C., Elisabeth I. Heath, Frank C. Cackowski, et al.. (2025). Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP). JCO Precision Oncology. 9(9). e2500457–e2500457.

Yap, Timothy A., Patricia LoRusso, Rowan Miller, et al.. (2025). The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study. British Journal of Cancer. 133(2). 168–177. 2 indexed citations

Smith, Julian R., Jelena Urosevic, S. Breanndan Moore, et al.. (2024). 146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies. European Journal of Cancer. 211. 114668–114668.

Shapiro, Geoffrey I., Bristi Basu, Anthony B. El-Khoueiry, et al.. (2023). 821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis). Annals of Oncology. 34. S542–S542. 2 indexed citations

Park, Sehhoon, Yu Jung Kim, Young Joo Min, et al.. (2023). Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer. 130(4). 541–552. 15 indexed citations

Karmokar, Ankur, Adina Hughes, Zena Wilson, et al.. (2023). Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models. Cancers. 15(16). 4195–4195. 4 indexed citations

Wethington, Stephanie L., Payal D. Shah, Lainie P. Martin, et al.. (2023). C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer. Clinical Cancer Research. 29(15). 2800–2807. 40 indexed citations

Vezyroglou, Aikaterini, John S. Thornton, Subhabrata Mitra, et al.. (2022). Broadband-NIRS System Identifies Epileptic Focus in a Child with Focal Cortical Dysplasia—A Case Study. Metabolites. 12(3). 260–260. 7 indexed citations

Kim, Seung Tae, Simon A. Smith, Peter G. Mortimer, et al.. (2021). Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical Cancer Research. 27(17). 4700–4709. 61 indexed citations

10.

Yap, Timothy A., Matthew Krebs, Sophie Postel‐Vinay, et al.. (2021). Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research. 27(19). 5213–5224. 71 indexed citations

11.

Willis, Sophie E., C Winkler, Martine P. Roudier, et al.. (2021). Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British Journal of Cancer. 125(12). 1666–1676. 31 indexed citations

12.

Mahdi, Haider, Navid Hafez, Deborah B. Doroshow, et al.. (2021). Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology. 5(5). 1432–1442. 56 indexed citations

13.

Brunner, Andrew M., Yiwen Liu, Lourdes Mendez, et al.. (2021). Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. Blood. 138(Supplement 1). 1521–1521. 6 indexed citations

14.

Goldberg, Frederick W., M. Raymond V. Finlay, Attilla Ting, et al.. (2019). The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. Journal of Medicinal Chemistry. 63(7). 3461–3471. 66 indexed citations

15.

O’Brien, Ciara, Louise Carter, Natalie Cook, & Emma Dean. (2017). Novel Early Phase Clinical Trial Design in Oncology. Pharmaceutical Medicine. 31(5). 297–307. 2 indexed citations

16.

Gupta, Avinash, Mahmood Ayub, Crispin Miller, et al.. (2017). Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling. Annals of Oncology. 28. v573–v573. 3 indexed citations

17.

Dean, Emma, Nicola Steele, Hendrik‐Tobias Arkenau, et al.. (2016). SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. Annals of Oncology. 27. vi439–vi439. 2 indexed citations

18.

Basu, Bristi, Emma Dean, M. Puglisi, et al.. (2015). First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research. 21(15). 3412–3419. 102 indexed citations

19.

Stovold, Rachel, Muhammad Babur, Kaye J. Williams, et al.. (2013). Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. British Journal of Cancer. 108(8). 1704–1711. 27 indexed citations

20.

Ranson, Malcolm, Emma Dean, Tim Ward, et al.. (2007). Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.. Molecular Cancer Therapeutics. 6.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact